Entrada Therapeutics (TRDA) Q1 2026 earnings snapshot

Entrada Therapeutics (TRDA) opened 2026 with Q1 revenue of US$0.9 million and a basic EPS loss of US$0.95, with trailing 12 month revenue at US$5.7 million and trailing EPS at a loss of US$4.00. Over recent quarters the company has seen revenue move from US$37.4 million and EPS of US$0.03 in Q4 2024 to US$20.6 million and EPS of US$0.63 in Q1 2025. This was accompanied by a shift from net income of US$65.6 million over the trailing 12 months to a loss of US$166.1 million by Q1 2026, putting the spotlight firmly on how quickly margins can improve from here.

See our full analysis for Entrada Therapeutics.

Next up is how these results line up with the widely followed stories around growth, profitability and risk that investors have been using to frame Entrada Therapeutics in the market.

TTM loss of US$166.1 million keeps profitability in focus

• Over the last twelve months, Entrada reported a net income loss of US$166.1 million on revenue of US$5.7 million, compared with a Q1 2026 net loss of US$39.7 million on US$0.9 million of revenue.
• What stands out for a bullish view is that revenue is forecast to grow about 49.8% per year, while losses have grown at roughly 2.3% per year over five years. Any optimism around future earnings has to reconcile strong top line forecasts with persistent negative net income.
  • This tension means bulls pointing to revenue growth need to square it with TTM EPS at a loss of US$4.00 and no profitability expected over the next three years in the data provided.
  • At the same time, the earnings profile gives plenty of data for cautious investors to point to when they highlight the risk that the business could keep absorbing capital without a clear path to profit in the near term.

High 43.6x P/S ratio versus peers

• The stock trades on a P/S of 43.6x compared with a US Biotechs industry average of 10.9x and a peer average of 2.9x, so investors are paying a much higher multiple of sales than the sector benchmarks.
• Critics highlight that this rich P/S multiple sits on top of TTM revenue of only US$5.7 million and a TTM net loss of US$166.1 million. This supports the bearish argument that a lot of future success is already priced in even though the company is not forecast to reach profitability in the next three years.
  • That bearish view is also supported by Q1 2026 revenue of US$0.9 million being well below the US$20.6 million reported in Q1 2025, so the current multiple is being applied to a smaller recent revenue base than in prior periods shown.
  • On the other hand, anyone arguing the valuation is justified tends to lean on the forecast 49.8% annual revenue growth in the data, which would need to eventually show up in earnings for the current P/S level to look comfortable.

Volatile share price with large implied upside

• Entrada trades at US$6.85, while analysts in aggregate are indicating a single allowed price target of US$21.40. This represents a very large premium to the current share price based on the inputs.
• Supporters of a bullish case point out that this gap between US$6.85 and the US$21.40 target sits alongside forecast 49.8% annual revenue growth. The same dataset notes high share price volatility over the past three months and no path to profitability over the next three years, which means the bullish thesis is heavily dependent on how investors treat that potential revenue growth during a period of ongoing losses.
  • For readers, the key question is whether the volatility mentioned alongside the rich P/S ratio and current losses simply reflects debate about those bullish expectations or whether it signals that the market is still trying to work out a comfortable trading range.
  • Either way, the combination of a very large gap to the price target, a US$166.1 million TTM loss and a 43.6x P/S multiple creates a setup where the stock can react sharply to new information about revenue or costs.

For a clearer sense of how other investors are weighing this mix of high growth forecasts, losses and volatility, it can help to read a range of views in one place, not just look at the latest quarter in isolation, so you may want to see what the broader community is saying about Entrada Therapeutics through the Curious how numbers become stories that shape markets? Explore Community Narratives

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Entrada Therapeutics's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

With such a split picture around growth expectations and ongoing losses, it helps to move quickly from headlines to the underlying data and make up your own mind. A good place to start is the 2 key rewards and 2 important warning signs.

Explore Alternatives

Entrada Therapeutics combines a TTM net loss of US$166.1 million, no expected profitability over the next three years and a 43.6x P/S multiple. This puts valuation and risk front and center.

If that mix of ongoing losses and high volatility feels uncomfortable, you may want to balance your portfolio by checking companies in the 72 resilient stocks with low risk scores that prioritize resilience and steadier fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.